What is Orforglipron?
Orforglipron is a novel, highly selective, non-peptide oral glucagon-like peptide-1 (GLP-1) receptor agonist. Unlike traditional peptide-based incretin mimetics that require subcutaneous injection, Orforglipron is a small-molecule compound engineered to withstand enzymatic degradation in the gastrointestinal tract, enabling complete oral bioavailability. Researchers study this compound primarily for its structural stability, chronic weight management mechanisms, and glycemic regulation properties.
For laboratory and in vitro evaluation, researchers often choose to buy Orforglipron in pure chemical reference form. Reconstituted matrices can be securely prepared using standard clinical vectors or specialized reconstitution solution protocols to maintain structural compound distribution during cellular screening assays.
Chemical and Molecular Data
| Compound Name | |
|---|---|
| Quantity | 12MG/ML |
| Synonyms / Alt Names | ; ; |
| CAS Number | 2212020-52-3 |
| Chemical Formula | C48H48F2N10O5 |
| Molecular Weight | 883.0 g/mol |
| IUPAC Name | 3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one |
| InChIKey | USUWIEBBBWHKNI-KHIFEHGGSA-N |
| SMILES Code | C[C@H]1C[C@]1(C2=NOC(=O)N2)N3C4=C(C=C(C=C4)[C@H]5CCOC(C5)(C)C)C=C3C(=O)N6CCC7=NN(C(=C7[C@@H]6C)N8C=CN(C8=O)C9=C(C1=C(C=C9)N(N=C1)C)F)C1=CC(=C(C(=C1)C)F)C |
What are the Mechanisms of Action?
The biochemical pathways and cellular targets of Orforglipron include:
- Non-Peptide GLP-1R Agonism: Research demonstrates that Orforglipron targets the glucagon-like peptide-1 receptor via an allosteric binding pocket distinct from endogenous GLP-1 peptides, inducing biased signaling cascades that prompt glucose-dependent insulin secretion.
- Enzymatic Hydrolysis Resistance: Because it lacks an amino acid backbone, the molecule completely avoids dipeptidyl peptidase-4 (DPP-4) degradation pathways, resulting in high metabolic stability and extended systemic transit cycles.
- Gastric Motility & Satiety Modulation: Preclinical models indicate clear concentration-dependent slowing of gastric emptying rates alongside central nervous system signaling activation within the arcuate nucleus to modulate satiety pathways.
What are the Clinical & Preclinical Trials on Orforglipron?
When evaluating research efficacy and published experimental literature for Orforglipron:
- Phase 2 Dose-Response Trial Evaluation: Clinical data published in ResearchGate evaluated oral Orforglipron protocols in patients with type 2 diabetes, demonstrating significant, dose-dependent reductions in mean HbA1c and body weight metrics over 26 weeks compared to placebo control baselines.
- Structural Bioavailability Dynamics: Comprehensive chemical dynamic profiles mapped via PMC Archive Reports highlight how the non-peptide matrix avoids early hepatic extraction, confirming efficient tracking across diverse systemic metabolic pathways without requiring absorption enhancers.
- Safety & Tolerability Metrics: Across multicentre randomizations, Orforglipron showcased a standard gastrointestinal adverse event profile similar to injectable options, characterized by transient, dose-escalating adaptions with clean safety metrics across hepatorenal parameters.
How does Orforglipron compare to other compounds?
To evaluate target specificity and absolute metabolic potency, researchers compare Orforglipron against established peptide incretin mimetics and modern co-agonists:
| Compound | Primary Target | Structural Modifications | Biological Impact / Receptor Affinity |
|---|---|---|---|
| Orforglipron | GLP-1 Receptor (Selective Allosteric Agonist) | Synthetic small-molecule non-peptide configuration | High oral bioavailability with direct resistance to DPP-4 enzymatic clearing cascades |
| Semaglutide (EA-1SG) | GLP-1 Receptor (Orthosteric Agonist) | Modified peptide sequence containing a C18 fatty diacid chain spacer | High receptor affinity with slow clearance, predominantly requiring subcutaneous distribution formats |
| Tirzepatide (EA-2TZ) | Dual GIP and GLP-1 Receptor Agonist | Synthetic peptide base attached to a C20 fatty diacid moiety | Synergistic complementary pathway activation optimizing insulin sensitizing mechanisms |
| Cagrilintide (EA-1C) | Amylin Receptor Agonist (Calcitonin/AMY Receptor Subtypes) | Long-acting acylated lipophilic peptide analog of human amylin | Promotes metabolic signal synergy via localized satiety controls independent of default incretin pathways |
Shipping & Returns
Same-Day Dispatch
Orders before 4 PM CT Mon–Fri ship same day. Weekend and holiday orders ship the next business day.
Carriers
U.S. shipping via FedEx. FedEx 2Day $15, FedEx Priority Overnight $60. Free shipping on U.S. orders over $200. Prices exclude tax.
Returns
Returns and exchanges for damaged or defective products only. Contact us within 14 days of delivery with your order number and photos.
Full details: Shipping Policy and Refund Policy.
Disclaimer: All compounds and research materials provided by Essential Aminos are strictly for laboratory and research professional use only. They are not approved for human or animal use nor consumption by the Food and Drug Administration (FDA). These products should not be used for any form of in vivo experimentation or for any other non-laboratory purpose. Any violation or indication of human or animal use will result in immediate removal from being able to purchase products in the future. By purchasing these products, you acknowledge that they will be used exclusively within a controlled and qualified research environment.
Certificate of Analysis
Certificates of analysis are provided for laboratory research reference. Expand a batch below to view the PDF. Only the newest three COAs for this product are listed here.
No certificate of analysis is currently linked to this product. Search by batch number on the COA Search page.
